Sotorasib FDA Approval Status
FDA Approved: No
Generic name: sotorasib
Company: Amgen Inc.
Treatment for: Non-Small Cell Lung Cancer
Sotorasib is a KRASG12C inhibitor in development for the treatment of patients with KRAS G12C-mutated locally advanced or metastatic non- small cell lung cancer (NSCLC), following at least one prior systemic therapy.
Development Timeline for sotorasib
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.